225 related articles for article (PubMed ID: 16734516)
21. Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E.
Fan J; Donkin J; Wellington C
Biofactors; 2009; 35(3):239-48. PubMed ID: 19472365
[TBL] [Abstract][Full Text] [Related]
22. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia.
Papassotiropoulos A; Lütjohann D; Bagli M; Locatelli S; Jessen F; Buschfort R; Ptok U; Björkhem I; von Bergmann K; Heun R
J Psychiatr Res; 2002; 36(1):27-32. PubMed ID: 11755458
[TBL] [Abstract][Full Text] [Related]
23. CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk.
Qureischie H; Heun R; Lütjohann D; Popp J; Jessen F; Ledschbor-Frahnert C; Thiele H; Maier W; Hentschel F; Kelemen P; Kölsch H
Brain Res; 2008 Sep; 1232():1-6. PubMed ID: 18680734
[TBL] [Abstract][Full Text] [Related]
24. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease.
Heverin M; Bogdanovic N; Lütjohann D; Bayer T; Pikuleva I; Bretillon L; Diczfalusy U; Winblad B; Björkhem I
J Lipid Res; 2004 Jan; 45(1):186-93. PubMed ID: 14523054
[TBL] [Abstract][Full Text] [Related]
25. Cellular mechanism of U18666A-mediated apoptosis in cultured murine cortical neurons: bridging Niemann-Pick disease type C and Alzheimer's disease.
Koh CH; Cheung NS
Cell Signal; 2006 Nov; 18(11):1844-53. PubMed ID: 16797161
[TBL] [Abstract][Full Text] [Related]
26. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.
Boissonneault V; Filali M; Lessard M; Relton J; Wong G; Rivest S
Brain; 2009 Apr; 132(Pt 4):1078-92. PubMed ID: 19151372
[TBL] [Abstract][Full Text] [Related]
27. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain.
Björkhem I
J Intern Med; 2006 Dec; 260(6):493-508. PubMed ID: 17116000
[TBL] [Abstract][Full Text] [Related]
28. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain.
Locatelli S; Lütjohann D; Schmidt HH; Otto C; Beisiegel U; von Bergmann K
Arch Neurol; 2002 Feb; 59(2):213-6. PubMed ID: 11843691
[TBL] [Abstract][Full Text] [Related]
29. Amyloid excess in Alzheimer's disease: what is cholesterol to be blamed for?
Ledesma MD; Dotti CG
FEBS Lett; 2006 Oct; 580(23):5525-32. PubMed ID: 16814780
[TBL] [Abstract][Full Text] [Related]
30. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
31. The effects of gender and CYP46 and apo E polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients treated with statins.
Vega GL; Weiner M; Kölsch H; von Bergmann K; Heun R; Lutjohan D; Nguyen A; Moore C
Curr Alzheimer Res; 2004 Feb; 1(1):71-7. PubMed ID: 15975088
[TBL] [Abstract][Full Text] [Related]
32. Protein-protein interactions in the assembly and subcellular trafficking of the BACE (beta-site amyloid precursor protein-cleaving enzyme) complex of Alzheimer's disease.
Parsons RB; Austen BM
Biochem Soc Trans; 2007 Nov; 35(Pt 5):974-9. PubMed ID: 17956258
[TBL] [Abstract][Full Text] [Related]
33. CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism.
Kölsch H; Lütjohann D; Jessen F; Popp J; Hentschel F; Kelemen P; Schmitz S; Maier W; Heun R
Eur Psychiatry; 2009 Apr; 24(3):183-90. PubMed ID: 19286353
[TBL] [Abstract][Full Text] [Related]
34. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease.
Papassotiropoulos A; Lütjohann D; Bagli M; Locatelli S; Jessen F; Rao ML; Maier W; Björkhem I; von Bergmann K; Heun R
Neuroreport; 2000 Jun; 11(9):1959-62. PubMed ID: 10884051
[TBL] [Abstract][Full Text] [Related]
35. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease.
Kölsch H; Lütjohann D; Ludwig M; Schulte A; Ptok U; Jessen F; von Bergmann K; Rao ML; Maier W; Heun R
Mol Psychiatry; 2002; 7(8):899-902. PubMed ID: 12232784
[TBL] [Abstract][Full Text] [Related]
36. Oxysterols and neurodegenerative diseases.
Björkhem I; Cedazo-Minguez A; Leoni V; Meaney S
Mol Aspects Med; 2009 Jun; 30(3):171-9. PubMed ID: 19248803
[TBL] [Abstract][Full Text] [Related]
37. Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease.
Solomon A; Leoni V; Kivipelto M; Besga A; Oksengård AR; Julin P; Svensson L; Wahlund LO; Andreasen N; Winblad B; Soininen H; Björkhem I
Neurosci Lett; 2009 Oct; 462(1):89-93. PubMed ID: 19560513
[TBL] [Abstract][Full Text] [Related]
38. Statins: drugs for Alzheimer's disease?
Eckert GP; Wood WG; Müller WE
J Neural Transm (Vienna); 2005 Aug; 112(8):1057-71. PubMed ID: 15682268
[TBL] [Abstract][Full Text] [Related]
39. Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans.
Farooqui AA; Ong WY; Horrocks LA; Chen P; Farooqui T
Brain Res Rev; 2007 Dec; 56(2):443-71. PubMed ID: 17959252
[TBL] [Abstract][Full Text] [Related]
40. Inflammation, genes and zinc in Alzheimer's disease.
Vasto S; Candore G; Listì F; Balistreri CR; Colonna-Romano G; Malavolta M; Lio D; Nuzzo D; Mocchegiani E; Di Bona D; Caruso C
Brain Res Rev; 2008 Jun; 58(1):96-105. PubMed ID: 18190968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
